ID

34408

Description

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01241708

Link

https://clinicaltrials.gov/show/NCT01241708

Keywords

  1. 1/17/19 1/17/19 -
  2. 10/1/20 10/1/20 -
  3. 10/5/20 10/5/20 - Sarah Riepenhausen
Copyright Holder

GSK group of companies

Uploaded on

January 17, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT01241708

Eligibility Multiple Myeloma NCT01241708

Criteria
Description

Criteria

confirmed diagnosis of multiple myeloma with either durie-salmon stage i, ii, or iii or iss stage i, ii or iii, less than 12 months since initiation of systemic therapy
Description

ID.1

Data type

boolean

≥8x106 cd34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants
Description

ID.2

Data type

boolean

age: 18-75 years at time of transplantation
Description

ID.3

Data type

boolean

kps 70-100%
Description

ID.4

Data type

boolean

recovery from complications of prior therapies
Description

ID.5

Data type

boolean

gender: there is no gender restriction
Description

ID.6

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
diagnosis other than multiple myeloma
Description

ID.7

Data type

boolean

chemotherapy or radiotherapy within 8 days of initiating treatment in this study
Description

ID.8

Data type

boolean

prior autologous or allogeneic transplantation (except as enrolled into this study)
Description

ID.9

Data type

boolean

uncontrolled bacterial, viral, fungal or parasitic infections
Description

ID.10

Data type

boolean

Similar models

Eligibility Multiple Myeloma NCT01241708

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
ID.1
Item
confirmed diagnosis of multiple myeloma with either durie-salmon stage i, ii, or iii or iss stage i, ii or iii, less than 12 months since initiation of systemic therapy
boolean
ID.2
Item
≥8x106 cd34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants
boolean
ID.3
Item
age: 18-75 years at time of transplantation
boolean
ID.4
Item
kps 70-100%
boolean
ID.5
Item
recovery from complications of prior therapies
boolean
ID.6
Item
gender: there is no gender restriction
boolean
Item Group
C0680251 (UMLS CUI)
ID.7
Item
diagnosis other than multiple myeloma
boolean
ID.8
Item
chemotherapy or radiotherapy within 8 days of initiating treatment in this study
boolean
ID.9
Item
prior autologous or allogeneic transplantation (except as enrolled into this study)
boolean
ID.10
Item
uncontrolled bacterial, viral, fungal or parasitic infections
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial